ZochertSOltmanKMElgersmaBMHellwigTRGulsethMP. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion. Am J Health Syst Pharm. 2019;76:505-511. doi:10.1093/ajhp/zxz013
3.
RobinsonZSHarperNG.Apixaban levels detected in a patient 10 days from last known dose while experiencing acute on chronic kidney disease. Ann Pharmacother. 2021;55:687-688. doi:10.1177/1060028020962794
4.
JanuaryCTWannSLAlpertJS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.
5.
BurnettAEMahanCEVazquezSROertelLBGarciaDAAnsellJ.Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206-232. doi:10.1007/s11239-015-1310-7
